Allergy Immunotherapy Clinical Practice Guidelines (2019)

European Academy of Allergy and Clinical Immunology

This is a quick summary of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

June 06, 2019

Guidelines for the use of house dust mites (HDM) allergy immunotherapy (AIT) as add‐on treatment for HDM‐driven allergic asthma were published in May 2019 by the European Academy of Allergy and Clinical Immunology.[1]

House dust mite (HDM) subcutaneous immunotherapy (SCIT) is recommended for children and adults with controlled HDM‐driven allergic asthma as an add‐on treatment to regular therapy to decrease symptoms and medication use.

HDM SCIT is recommended for adults with controlled HDM‐driven allergic asthma as the add‐on treatment to regular therapy to decrease allergen‐specific airway hypersensitivity and to improve quality of life.

HDM sublingual immunotherapy (SLIT) drops are recommended for children with controlled HDM‐driven allergic asthma as an add‐on treatment to decrease symptoms and medication use.

HDM SLIT‐tablets are recommended for adults with controlled and partially controlled HDM‐driven allergic asthma as an add‐on treatment to regular therapy to decrease exacerbations and to improve asthma control.

For more Clinical Practice Guidelines, go to Guidelines.

For more information, go to Allergic and Environmental Asthma.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....